Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

½Å»ý¾Æ ´ãÁó Á¤Ã¼Áõ¿¡¼­ ¹«´ãÁóº¯ÀÇ À¯¹«¿Í Tc99m DISIDA °£´ãµµ ÁÖ»ç °á°ú°£ÀÇ »ó°ü¼º°ú »ýÈ­ÇÐÀû °Ë»çÀÇ Â÷ÀÌ¿¡ °üÇÑ ¿¬±¸ The Correlation between Acholic Stool and the Result of Tc99m DISIDA Hepatobiliary Scintigraphy and Biochemical Test in Neonatal Cholestasis

´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸÁö 2002³â 5±Ç 1È£ p.51 ~ 61
ÁÖÀº¿µ, ¾È¿¬¸ð, ±è¿ëÁÖ, ¹®¼öÁö, ÃÖÀ±¿µ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÁÖÀº¿µ ( Joo Eun-Young ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

¾È¿¬¸ð ( Ahn Yeon-Mo ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
±è¿ëÁÖ ( Kim Yong-Joo ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¹®¼öÁö ( Moon Su-Ji ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÃÖÀ±¿µ ( Choi Yun-Young ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ÇÙÀÇÇб³½Ç

Abstract

¸ñÀû: ½Å»ý¾Æ ´ãÁó Á¤Ã¼Áõ ȯ¾ÆÀÇ °¨º°À» À§ÇØ Tc99m DISIDA °£´ãµµ ÁÖ»ç °Ë»ç »ó ½Å»ý¾Æ °£¿°°ú °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõÀÇ ÀÓ»óÁõ»ó, ÀÌÇмҰß, »ýÈ­ÇÐ °Ë»ç µîÀ» ºñ±³ÇÏ°í, ¹«´ãÁ󺯰ú Tc99m DISIDA °£´ãµµ ÁÖ»ç °Ë»çÀÇ °ü·Ã¼ºÀ» ºñ±³ÇÔÀ¸·Î¼­ Áø´Ü¿¡ µµ¿òÀ» ¾ò°íÀÚ ÇÏ¿´´Ù.

¹æ¹ý: 1993³â 6¿ùºÎÅÍ 2001³â 1¿ù±îÁö ÇѾç´ëÇк´¿ø ¼Ò¾Æ°ú ¹× ¼Ò¾Æ¿Ü°ú¿¡ Á÷Á¢¹ÝÀÀÇü °íºô¸®·çºóÇ÷ÁõÀ» ÁÖ¼Ò·Î ÀÔ¿øÇß´ø 4°³¿ù ¹Ì¸¸ÀÇ È¯¾Æ Áß Tc99m DISIDA °£´ãµµ Áֻ縦 ½ÃÇàÇÑ 29¸íÀÇ È¯¾ÆµéÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. ÀÌ Áß °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõÀº 9¸íÀÌ°í ½Å»ý¾Æ °£¿°Àº 20¸íÀ¸·Î ÀÓ»óÁõ»ó ¹× ÀÌÇÐÀû ¼Ò°ß, »ýÈ­ÇÐÀû °Ë»ç, Tc99m DISIDA °£´ãµµ ÁÖ»ç °á°ú¸¦ Á¶»çÇÏ¿´´Ù.

°á°ú: 1) °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõ ȯ¾Æ°¡ ½Å»ý¾Æ °£¿°º¸´Ù ´õ »¡¸® Áø´ÜµÇ°í, µÎ Áý´Ü ¸ðµÎ Á¤»óüÁß, ¸¸»è¾Æ°¡ ´ëºÎºÐÀÌ°í, ³²¾Æ¿¡¼­ È£¹ßÇß´Ù. Ȳ´ÞÀº µÎ Áý´Ü ¸ðµÎ¿¡°Ô, ¹«´ãÁóº¯Àº °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõ ȯ¾Æ ¸ðµÎ¿¡°Ô ³ªÅ¸³µÀ¸¸ç ½Å»ý¾Æ °£¿°Àº ¹«´ãÁóº¯ÀÌ 10%¿¡¼­¸¸ ³ªÅ¸³µ´Ù. 2) ³»¿ø ´ç½Ã °Ë»ç»ó direct bilirubinÀÌ °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõÀÏ ¶§´Â 6 2.6 §·/§£, ½Å»ý¾Æ °£¿°Àº 4.0 2.5 §·/§£·Î °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõ¿¡¼­ À¯ÀÇÇÏ°Ô Áõ°¡µÇ¾ú°í, °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõÀº ¼Òº¯ bilirubinÀÌ ´õ ¸¹ÀÌ ³ªÅ¸³µ´Ù. 3) °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõ¿¡¼­ direct bilirubin, total bilirubin, ALT, AST, ALPÀÇ Á¤»óÈ­µÇ´Â ±â°£ÀÌ Á» ´õ ¿À·¡ °É·È´Ù. bilirubin ¼öÄ¡ÀÇ È£ÀüÀ» º¸ÀÌ´Â ºñÀ²Àº ºñ½ÁÇß°í °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõÀÌ ½ÉÈ­µÇ´Â °æ¿ì°¡ 22.2%·Î ´õ ¸¹¾Ò°í ÁÖ·Î ¼ö¼ú ÈÄ ºÎÀÛ¿ë¿¡ ÀÇÇÑ °ÍÀ̾ú´Ù. 4) ¹«´ãÁóº¯ È¯¾Æ Áß¿¡ Tc99m DISIDA °£´ãµµ ÁÖ»ç »ó ¼ÒÀå ³» ¹æ»çÈ°¼ºÀÌ Àִ ȯ¾Æ°¡ 18.2%¿´°í, ¹æ»çÈ°¼ºÀÌ ¾ø´Â ȯ¾Æ°¡ 81.8%·Î ³ªÅ¸³µ°í, °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõÀ¸·Î ÆÇ´ÜµÇ¾î ¼ö¼úÇÑ È¯¾Æ°¡ 63.6%·Î ³ªÅ¸³µ´Ù. 5) ¹«´ãÁóº¯ ¿©ºÎ¿Í Tc99m DISIDA °£´ãµµ ÁÖ»ç °á°ú°£ÀÇ »ó°ü°è¼ö¿¡¼­ r °ªÀº -0.858·Î¼­ Àý´ë°ªÀÌ 1¿¡ °¡±õ°í À½¼ö·Î ÀÌ´Â ¿ª»ó°ü
°ü°è°¡ ³ô¾Æ ¹«´ãÁóº¯ È¯¾Æ¿Í ¹æ»çÈ°¼ºÀÌ ¾øÀ» °æ¿ì, ´ãÁóº¯ È¯¾Æ¿Í ¹æ»çÈ°¼ºÀÌ ÀÖ´Â °æ¿ì°£ »ó°ü°ü°è°¡ ³ô°Ô ³ªÅ¸³µ´Ù. 6) ¹«´ãÁóº¯ È¯¾Æ Áß Tc99m DISIDA °£´ãµµ ÁÖ»ç °Ë»ç »ó ¼ÒÀå ³» ¹æ»çÈ°¼ºÀÌ ¾ø´Â ȯ¾Æ¿¡¼­ total bilirubinÀÌ À¯ÀÇÇÏ°Ô Áõ°¡µÇ¾î ÀÖ°í, direct bilirubin, total bilirubin, ALT, ASTµµ Áõ°¡µÇ¾î ÀÖ¾úÀ¸³ª À¯ÀÇÇÏÁö´Â ¾Ê¾Ò´Ù. 7) Tc99m DISIDA °£´ãµµ ÁÖ»ç °Ë»ç »ó ¼ÒÀå ³» ¹æ»çÈ°¼ºÀÌ Àִ ȯ¾Æ Áß ¹«´ãÁóº¯ÀÌ ¾ø´Â °æ¿ì¿¡ ALT°¡ À¯ÀÇÇÏ°Ô ³ô¾Ò°í, direct bilirubin, total bilirubin, AST´Â À¯ÀÇÇÏÁö ¾Ê°Ô ³ô¾ÒÀ¸¸ç ¹«´ãÁóº¯ÀÏ °æ¿ì¿¡´Â ALP, ¼Òº¯ bilirubin ¾ç¼º·üÀÌ ´õ ³ô¾ÒÁö¸¸ À¯ÀÇÇÏÁö´Â ¾Ê¾Ò´Ù. ±×·¯³ª ÀÌ¿¡ ´ëÇؼ­´Â ´õ ¸¹Àº ȯÀÚ¿¡ ´ëÇÑ °Ë»ç°¡ ÇÊ¿äÇϸ®¶ó »ý°¢µÈ´Ù.

°á·Ð: °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõ ȯ¾Æ´Â ¹«´ãÁóº¯, direct bilirubin 4 §·/§£ ÀÌ»ó, ¼Òº¯ bilirubin ¾ç¼º, Tc99m DISIDA °£´ãµµ ÁÖ»ç °Ë»ç »ó ¹æ»çÈ°¼ºÀÌ ¾øÀ» ¶§ °¡´É¼ºÀÌ ³ô´Ù. °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõ¿¡¼­ ¼ö¼ú ÈÄ °Ë»ç°á°úÀÇ Á¤»óÈ­µÇ´Â ±â°£ÀÌ Á» ´õ ¿À·¡ °É¸®°í, È£ÀüµÇ´Â °æ¿ì´Â °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõ, ½Å»ý¾Æ °£¿°ÀÌ °¢°¢ 66.7%, 70%·Î µÎ ±ºÀÌ ºñ½ÁÇß´Ù. ½ÉÈ­µÇ´Â °æ¿ì´Â °£¿Ü ´ãµµ Æó¼âÁõ ÀÇÁõ¿¡¼­ ´õ ¸¹¾Ò°í ÁÖ·Î ¼ö¼ú ÈÄ ºÎÀÛ¿ë¿¡ ÀÇÇÑ °ÍÀ¸·Î »ý°¢µÇ¸ç ¿ÀÈ÷·Á ¼ö¼úÇÏÁö ¾ÊÀº 2¸í¿¡¼­ Ưº°ÇÑ Ä¡·á ¾øÀÌ È£Àü ¾ç»óÀ» º¸À̱⵵ Çß´Ù. ¹«´ãÁóº¯ È¯¾Æ Áß ¹æ»çÈ°¼ºÀÌ ¾ø´Â ȯ¾Æ¿¡¼­ total bilirubinÀÌ À¯ÀÇÇÏ°Ô Áõ°¡µÇ¾ú°í, ¹æ»çÈ°¼ºÀÌ Àִ ȯ¾Æ Áß ¹«´ãÁóº¯ÀÌ ¾ø´Â °æ¿ì¿¡ ALT°¡ ¿ÀÈ÷·Á À¯ÀÇÇÏ°Ô Áõ°¡µÇ¾úÀ¸³ª ´õ ¸¹Àº ȯÀÚ±º¿¡ ´ëÇÑ ¿¬±¸°¡ ÇÊ¿äÇϸ®¶ó º»´Ù. ¹«´ãÁ󺯰ú ¼ÒÀå ³» ¹æ»çÈ°¼ºÀÌ ¾ø´Â °æ¿ì°£¿¡´Â À¯ÀÇÇÑ »ó°ü°ü°è°¡ ÀÖÁö¸¸ ¹«´ãÁóº¯ 11¸í Áß 2¸í(18.2%)¿¡¼­ ¼ÒÀå ³» ¹æ»çÈ°¼ºÀÌ °üÂûµÇ¾ú´Ù´Â Á¡, ¼ÒÀå ³» ¹æ»çÈ°¼ºÀÌ ¾ø´Â ȯ¾Æ 9¸íÁß ¼ö¼ú ¾øÀ̵µ È£ÀüµÈ ȯ¾Æ°¡ 2¸í(22.2%)À¸·Î °üÂûµÇ¾ú´Ù´Â Á¡µîÀº ¹«´ãÁóº¯ÀÌ ÀÖ´Ù´Â °Í°ú ¼ÒÀå ³» ¹æ»çÈ°¼ºÀÌ ¾ø´Ù´Â °Í¸¸À¸·Î °£¿Ü ´ãµµ Æó¼âÁõÀ¸·Î ÆÇ´ÜµÉ ¼ö ¾øÀ¸¸ç °æÇÇ °£Ä§ »ý°ËÀ̳ª ½ÃÇè
°³º¹¼ú·Î È®ÁøÇÏ¿©¾ß ÇÑ´Ù´Â °ÍÀ» ¸»ÇØ ÁØ´Ù.

Purpose: The most common causes of neonatal cholestasis are neonatal hepatitis (NH) and extrahepatic biliary atresia (EHBA). Since neonatal cholestasis presents with variable expression of same pathologic process and has similar clinical, biochemical, and histologic features between EHBA and idiopathic neonatal hepatitis (NH), differential diagnosis is often difficult. We reviewed the differences of clinical characteristics and laboratory data to find out any correlation between
the results of Tc99m DISIDA scan and presence of acholic stool.

Methods: Between June 1993 and January 2001, total 29 infants younger than 4 month-old underwent Tc99m DISIDA scan. Their biochemical tests and clinical course were reviewed retrospectively.

Results: Patients who had negative intestinal activity on Tc99m DISIDA scan showed acholic stool and revealed higher serum direct bilirubin and urine bilirubin level. 18.2% of patients with acholic stool showed intestinal activity on Tc99m DISIDA scan and 81.8% of them did not. All the patients without acholic stool showed positive intestinal activity on Tc99m DISIDA scan. The result of Tc99m DISIDA scan and the presence of acholic stool showed high negative correlation (r : 0.858). Patients with acholic stool and negative intestinal activity on Tc99m DISIDA scan showed higher serum total bilirubin level. Patients without acholic stool and positive intestinal activity on Tc99m DISIDA scan showed higher serum level of ALT.

Conclusion: Patients with acholic stool and negative intestinal activity showed high correlation, but 18.2% of patients with acholic stool showed positive intestinal activity. So operative cholangiogram or transcutaneous liver biopsy should be performed for confirmation.

Å°¿öµå

Neonatal hepatitis;Extrahepatic biliary atresia;Tc99m DISIDA scan;Acholic stool

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS